StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
JPMorgan Downgrades Novavax (NVAX) to Neutral
May 12, 2021 5:45 AM
JPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Downgrades
Next Articles
Form 8-K NOVAVAX INC For: May 10
May 11, 2021 5:18 PM
Novavax (NVAX) PT Lowered to $235 at Jefferies After Rollout Delay Concedes First Mover Advantage
May 11, 2021 10:42 AM
Form 10-Q NOVAVAX INC For: Mar 31
May 10, 2021 4:18 PM
Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat
May 10, 2021 4:04 PM
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 4:02 PM
Novavax (NVAX) weekly option IV at 125 into quarter results and outlook
May 10, 2021 10:17 AM
Novavax (NVAX) Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
May 10, 2021 9:13 AM
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
May 10, 2021 9:12 AM
Novavax (NVAX) Unlikely to Seek Vaccine Emergency Use Until June - Washington Post
May 10, 2021 8:46 AM
